- Full Text
- Scholarly Journal
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers
Blood Cancer Journal
; London Vol. 15, Iss. 1, (Dec 2025): 45.
DOI:10.1038/s41408-025-01257-1
PDF
CiteCite
Copy URL
https://www.proquest.com/scholarly-journals/outcomes-patients-with-classic-hodgkin-lymphoma/docview/3181528186/se-2?accountid=208611
PrintAll Options